Dr. Reddy's Laboratories acquires UCB portfolio RA treatments to reach $9.3 billion in U.S. by 2020 Teva launches generic Exforge tabs Report: FDA's Office of Generic Drugs takes medical leave Amneal to acquire Actavis Australia’s generics business Teva to strengthen CNS portfolio with Auspex acquisition FDA revisits label changes with public meeting At the scene of NACDS RxIMPACT Day Dr. Reddy’s to expand access to Hepatitis C drug Wright to lead business development at Teva First Previous 319 320 321 322 323 Next Last